Brief: Innovation Pharma Provides Study Details For Ongoing Phase 2 Clinical Trial Of Brilacidin In Hospitalized Covid-19 Patients
26/02/2021 15:03
Feb 26 (Reuters) - Innovation Pharmaceuticals Inc IPIX.PK :
* INNOVATION PHARMA PROVIDES STUDY DETAILS FOR ONGOING PHASE
2
CLINICAL TRIAL OF BRILACIDIN IN HOSPITALIZED COVID-19 PATIENTS
Source text for Eikon: ID:nGNX5kx6fq
Further company coverage: IPIX.PK
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Innovation Pharmaceuticals
See all newsBrief: Innovation Pharmaceuticals Announces New Milestone At Beamed On Track To File 510(K) Submission To FDA In Q2 2024
Brief: Innovation Pharmaceuticals Provides Update On US Patent Applications Covering Use Of Brilacidin In Inflammatory Bowel Diseases, Coronaviruses And Fungal Diseases
Brief: Innovation Pharma Reports Enrollment In Phase 2 Trial Of Brilacidin For COVID-19 Tops 70%
Brief: Innovation Pharma Surpasses 50% Enrollment In Phase 2 Clinical Trial Of Brilacidin For COVID-19
Brief: Innovation Pharma Completes Interim Safety Data Review